Since many years Chimerigen Laboratories, LLC (Chimerigen) develops, manufactures and markets high quality and leading edge proteins for biomedical and immunology research. One of Chimerigen's specialty is the production of unique immunoglobulin based chimeric fusion proteins using advanced cellular and molecular biological techniques. These reagents are used successfully in basic and applied research. AdipoGen has now become a trusted and reliable marketing and sales partner for Chimerigen's product panel. Because of the high performance characteristics and quality the Chimerigen fusion proteins are widely recognized reagents and are cited in many scientific publications.

Non-lytic Ig-based Chimeric Fusion Cytokines with Long Circulating Half-life

The potential clinical application of cytokines to modulate immune responses is very high. Unfortunately, most cytokines have short circulating half-lives. Therefore, to facilitate the study of cytokine effects in vivo, a variety of non-lytic immunoglobulin-based chimeric cytokine fusion proteins have been created, in which a cytokine sequence had been genetically fused to the hinge, CH2 and CH3 regions of an immunoglobulin. 

These non-lytic fusion proteins possess both the biological functions of the cytokine moiety and a prolonged circulating half-life determined by the Fc domain. Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the fusion proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC). These fusion molecules also have the promise of being minimally to negligibly immunogenic since they are made entirely from elements derived from the species to be treated.

     
Figure: General structure of mouse non-lytic fusion proteins.

Literature:
Localization of the binding site for the human high-affinity Fc receptor on IgG: A.R. Duncan, et al.; Nature 332, 563 (1988)
The binding site for Clq on IgG: A.R. Duncan & G. Winter; Nature 332, 738 (1988)
Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation: X.X. Zheng, et al.; J. Immunol. 154, 5590 (1995)